Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
12 p, 506.4 KB Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia / Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ; DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ; Chromik, Jörg (Goethe University Frankfurt) ; Chatterjee, Manik (University Hospital of Würzburg) ; Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ; de Vos, Filip (University Medical Center Utrecht) ; Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Cassier, Philippe A. (Léon Bérard Center) ; Tai, David (National Cancer Center Singapore) ; Kiladjian, Jean-Jacques (Université de Paris) ; Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ; Mous, Rogier (University Medical Center Utrecht) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ; Ferretti, Stephane (Novartis Institutes for Biomedical Research) ; Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ; Meille, Christophe (Novartis Institutes for Biomedical Research) ; Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ; Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Mariconti, Luisa (Novartis Institutes for Biomedical Research) ; Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ; Fabre, Claire (Novartis Institutes for Biomedical Research) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881  
2.
30 p, 7.5 MB The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Sammut, Stephen-John (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Ross, Edith M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Bashford-Rogers, Rachael (Department of Medicine. University of Cambridge) ; Greenstein, Erez (Weizmann Institute of Science (Israel). Department of Immunology) ; Markus, Havell (Mayo Clinic Center for Individualized Medicine) ; Morganella, Sandro (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Teng, Yvonne (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ; Maruvka, Yosef (Massachusetts General Hospital (Boston)) ; Pereira, Bernard (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Rueda, Oscar M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Chin, Suet-Feung (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Contente-Cuomo, Tania (Mayo Clinic Center for Individualized Medicine) ; Mayor, Regina (Centro de Investigación Biomédica en Red de Cáncer) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Ali, H. Raza (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Cope, Wei (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Tiezzi, Daniel (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Dariush, Aliakbar (Institute of Astronomy. University of Cambridge) ; Dias Amarante, Tauanne (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Reshef, Dan (Weizmann Institute of Science (Israel). Department of Immunology) ; Ciriaco, Nikaoly (Hospital Universitari Vall d'Hebron) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Vassiliou, George (Wellcome Trust/MRC Cambridge Stem Cell Institute) ; Getz, Gad (Massachusetts General Hospital (Boston)) ; Nik-Zainal, Serena (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Murtaza, Muhammed (Mayo Clinic Center for Individualized Medicine) ; Friedman, Nir (Weizmann Institute of Science (Israel). Department of Immunology) ; Markowetz, Florian (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Caldas, Carlos (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ; Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10  

Vea también: autores con nombres similares
1 Pereira, B. A.
1 Pereira, Beatriz Passamai
1 Pereira, Bruno
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.